159 related articles for article (PubMed ID: 33297311)
1. Paraoxonase-2 Silencing Enhances Sensitivity of A375 Melanoma Cells to Treatment with Cisplatin.
Campagna R; Bacchetti T; Salvolini E; Pozzi V; Molinelli E; Brisigotti V; Sartini D; Campanati A; Ferretti G; Offidani A; Emanuelli M
Antioxidants (Basel); 2020 Dec; 9(12):. PubMed ID: 33297311
[TBL] [Abstract][Full Text] [Related]
2. Modulation of chemoresistance by lysophosphatidic acid (LPA) signaling through LPA
Minami K; Ueda N; Maeda H; Ishimoto K; Otagaki S; Tsujiuchi T
Biochem Biophys Res Commun; 2019 Sep; 517(2):359-363. PubMed ID: 31362892
[TBL] [Abstract][Full Text] [Related]
3. Nicotinamide N-methyltransferase gene silencing enhances chemosensitivity of melanoma cell lines.
Campagna R; Salvolini E; Pompei V; Pozzi V; Salvucci A; Molinelli E; Brisigotti V; Sartini D; Campanati A; Offidani A; Emanuelli M
Pigment Cell Melanoma Res; 2021 Nov; 34(6):1039-1048. PubMed ID: 34018676
[TBL] [Abstract][Full Text] [Related]
4. Senescence-associated secretory factors induced by cisplatin in melanoma cells promote non-senescent melanoma cell growth through activation of the ERK1/2-RSK1 pathway.
Sun X; Shi B; Zheng H; Min L; Yang J; Li X; Liao X; Huang W; Zhang M; Xu S; Zhu Z; Cui H; Liu X
Cell Death Dis; 2018 Feb; 9(3):260. PubMed ID: 29449532
[TBL] [Abstract][Full Text] [Related]
5. Involvement of LPA receptor-5 in the enhancement of cell motile activity by phorbol ester and anticancer drug treatments in melanoma A375 cells.
Fukushima K; Takahashi K; Kurokawa A; Ishimoto K; Otagaki S; Minami K; Fukushima N; Honoki K; Tsujiuchi T
Biochem Biophys Res Commun; 2018 Jan; 496(1):225-230. PubMed ID: 29309788
[TBL] [Abstract][Full Text] [Related]
6. Bladder Cancer Chemosensitivity is Affected by Paraoxonase-2 Expression.
Fumarola S; Cecati M; Sartini D; Ferretti G; Milanese G; Galosi AB; Pozzi V; Campagna R; Morresi C; Emanuelli M; Bacchetti T
Antioxidants (Basel); 2020 Feb; 9(2):. PubMed ID: 32093309
[TBL] [Abstract][Full Text] [Related]
7. Paraoxonase-2 shRNA-mediated gene silencing suppresses proliferation and migration, while promotes chemosensitivity in clear cell renal cell carcinoma cell lines.
Schiavoni V; Emanuelli M; Campagna R; Cecati M; Sartini D; Milanese G; Galosi AB; Pozzi V; Salvolini E
J Cell Biochem; 2024 May; ():. PubMed ID: 38706121
[TBL] [Abstract][Full Text] [Related]
8. Influence of onconase in the therapeutic potential of PARP inhibitors in A375 malignant melanoma cells.
Raineri A; Prodomini S; Fasoli S; Gotte G; Menegazzi M
Biochem Pharmacol; 2019 Sep; 167():173-181. PubMed ID: 31185226
[TBL] [Abstract][Full Text] [Related]
9. Influence of therapy on the antioxidant status in patients with melanoma.
Gadjeva V; Dimov A; Georgieva N
J Clin Pharm Ther; 2008 Apr; 33(2):179-85. PubMed ID: 18315784
[TBL] [Abstract][Full Text] [Related]
10. Induction of apoptosis and/or necrosis following exposure to antitumour agents in a melanoma cell line, probably through modulation of Bcl-2 family proteins.
Shibuya H; Kato Y; Saito M; Isobe T; Tsuboi R; Koga M; Toyota H; Mizuguchi J
Melanoma Res; 2003 Oct; 13(5):457-64. PubMed ID: 14512787
[TBL] [Abstract][Full Text] [Related]
11. Addition of dacarbazine or cisplatin to interferon-alpha/interleukin-2 in metastatic melanoma: toxicity and immunological effects.
Keilholz U; Scheibenbogen C; Möhler T; Brossart P; Maclachlan D; Geueke AM; Jochim A; Hunstein W
Melanoma Res; 1995 Aug; 5(4):283-7. PubMed ID: 7496166
[TBL] [Abstract][Full Text] [Related]
12. Gambogic Acid Inhibits Melanoma through Regulation of miR-199a-3p/ZEB1 Signalling.
Liang L; Zhang Z; Qin X; Gao Y; Zhao P; Liu J; Zeng W
Basic Clin Pharmacol Toxicol; 2018 Dec; 123(6):692-703. PubMed ID: 29959879
[TBL] [Abstract][Full Text] [Related]
13. SIRT3 Silencing Sensitizes Breast Cancer Cells to Cytotoxic Treatments Through an Increment in ROS Production.
Torrens-Mas M; Pons DG; Sastre-Serra J; Oliver J; Roca P
J Cell Biochem; 2017 Feb; 118(2):397-406. PubMed ID: 27420645
[TBL] [Abstract][Full Text] [Related]
14. Depletion of CD147 sensitizes human malignant melanoma cells to hydrogen peroxide-induced oxidative stress.
Li J; Peng L; Wu L; Kuang Y; Su J; Yi M; Hu X; Li D; Xie H; Kanekura T; Chen X
J Dermatol Sci; 2010 Jun; 58(3):204-10. PubMed ID: 20451353
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
[TBL] [Abstract][Full Text] [Related]
16. Targeting nodal in conjunction with dacarbazine induces synergistic anticancer effects in metastatic melanoma.
Hardy KM; Strizzi L; Margaryan NV; Gupta K; Murphy GF; Scolyer RA; Hendrix MJ
Mol Cancer Res; 2015 Apr; 13(4):670-80. PubMed ID: 25767211
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of MUTYH contributes to cisplatin‑resistance of esophageal squamous cell carcinoma cells by promoting Twist‑mediated EMT.
Guo Y; Jia Y; Wang S; Liu N; Gao D; Zhang L; Lin Z; Wang S; Kong F; Peng C; Liu Y
Oncol Rep; 2019 Dec; 42(6):2716-2727. PubMed ID: 31578574
[TBL] [Abstract][Full Text] [Related]
18. NAD(P)H:Quinone Oxidoreductase-1 Expression Sensitizes Malignant Melanoma Cells to the HSP90 Inhibitor 17-AAG.
Kasai S; Arakawa N; Okubo A; Shigeeda W; Yasuhira S; Masuda T; Akasaka T; Shibazaki M; Maesawa C
PLoS One; 2016; 11(4):e0153181. PubMed ID: 27045471
[TBL] [Abstract][Full Text] [Related]
19. Combination of ω-3 fatty acids and cisplatin as a potential alternative strategy for personalized therapy of metastatic melanoma: an in-vitro study.
Ottes Vasconcelos R; Serini S; de Souza Votto AP; Santos Trindade G; Fanali C; Sgambato A; Calviello G
Melanoma Res; 2019 Jun; 29(3):270-280. PubMed ID: 30550405
[TBL] [Abstract][Full Text] [Related]
20. Cudraflavone C Induces Apoptosis of A375.S2 Melanoma Cells through Mitochondrial ROS Production and MAPK Activation.
Lee CW; Yen FL; Ko HH; Li SY; Chiang YC; Lee MH; Tsai MH; Hsu LF
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28703746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
